Recombinant Human CTSD, His-tagged, C13&N15 Labeled
|Product Overview :||Recombinant Human CTSD MS Standard Protein, C13 and N15-labeled (CTSD / Cathepsin D, Heavy Labeled) Ser 19 - Leu 412 (Accession # NP_001900) was produced in human 293 cells (HEK293) with fully chemically defined cell culture medium to obtain >99% incorpor|
- Gene Information
- Related Products
|Description :||Cathepsin D is also known as CTSD, CPSD, which belongs to the peptidase A1 family. Cathepsin D can be cleaved into the following 2 chains: cathepsin D light chain and cathepsin D heavy chain, which is expressed in the aorta extrcellular space (at protein level). The catalytic activity of Cathepsin D is specificity similar to, but narrower than, that of pepsin A. Cathepsin D does not cleave the 4-Gln-|-His-5 bond in B chain of insulin. Cathepsin D involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease.|
|Predicted N Terminal :||Ser 19|
|Form :||Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.|
|Molecular Mass :||CTSD / Cathepsin D, Heavy Labeled is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 43.6 kDa. The predicted N-terminus is Ser 19. DTT-reduced Protein migrates as 45-55 kDa in SDS-PAGE due to glycosylation.CTSD / Cathepsin D,|
|Endotoxin :||Less than 1.0 EU per μg of the CTSD / Cathepsin D, Heavy Labeled by the LAL method.|
|Purity :||>95% as determined by SDS-PAGE.|
|Applications :||MS Standard Protein|
|Storage :||Avoid repeated freeze-thaw cycles.No activity loss was observed after storage at:In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC).|
|Gene Name :||CTSD cathepsin D [ Homo sapiens ]|
|Official Symbol :||CTSD|
|Synonyms :||CTSD; cathepsin D; cathepsin D (lysosomal aspartyl protease) , CPSD; ceroid lipofuscinosis; neuronal 10; CLN10; lysosomal aspartyl protease; lysosomal aspartyl peptidase; ceroid-lipofuscinosis, neuronal 10; CPSD; MGC2311;|
|Gene ID :||1509|
|mRNA Refseq :||NM_001909|
|Protein Refseq :||NP_001900|
|UniProt ID :||P07339|
|Chromosome Location :||11p15.5|
|Pathway :||Ceramide signaling pathway, organism-specific biosystem; Direct p53 effectors, organism-specific biosystem; LKB1 signaling events, organism-specific biosystem; Lysosome, organism-specific biosystem; Lysosome, conserved biosystem; Tuberculosis, organism-specific biosystem; Tuberculosis, conserved biosystem;|
|Function :||aspartic-type endopeptidase activity; peptidase activity;|
|◆ Recombinant Protein|
|CTSD-913R||Recombinant Rhesus Macaque CTSD Protein, His (Fc)-Avi-tagged||+Inquiry|
|CTSD-877H||Recombinant Human CTSD Protein, His-tagged||+Inquiry|
|Ctsd-2369M||Recombinant Mouse Ctsd Protein, His-tagged||+Inquiry|
|CTSD-2752H||Recombinant Human CTSD Protein, His (Fc)-Avi-tagged||+Inquiry|
|CTSD-2103H||Recombinant Human CTSD Protein, GST-tagged||+Inquiry|
|◆ Native Protein|
|CTSD-5325D||Active Native Human CTSD protein||+Inquiry|
|CTSD-27858TH||Native Human CTSD||+Inquiry|
|CTSD-1648H||Active Native Human Cathepsin D||+Inquiry|
|CTSD-1735HCL||Recombinant Human CTSD cell lysate||+Inquiry|
|CTSD-3023MCL||Recombinant Mouse CTSD cell lysate||+Inquiry|
|◆ Assay kits|
|Kit-0264||Cathepsin D Inhibitor Screening Kit||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
There is an association between CTSD proteins and cognitive function. In some neurodegenerative diseases, abnormal accumulation and deposition of CTSD proteins may affect neuronal signaling and synaptic function, leading to a decline in cognitive function.
In some neurodegenerative diseases, levels of the CTSD protein may change. For example, people with Alzheimer's disease may have elevated levels of the CTSD protein. These changes may help in the diagnosis of the disease and in the assessment of the course of the disease.
For people with cognitive decline, their CTSD protein levels can be assessed by a blood or cerebrospinal fluid sample. This evaluation can help doctors understand whether the cause of cognitive decline is related to a neurodegenerative disease.
It is currently no treatment that directly targets the CTSD protein. However, some medications can reduce symptoms of neurodegenerative diseases, such as cholinesterase inhibitors such as donepezil, which can increase acetylcholine levels in synapses, which can improve cognitive function.
People with Parkinson's disease may have reduced levels of the CTSD protein. This decrease may be associated with neuronal death and impaired synaptic function. In addition, CTSD protein may also be associated with motor symptoms in patients with Parkinson's disease.
CTSD proteins play a role in Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. It may change in these diseases, leading to structural alterations and impaired signaling of neuronal synapses.
Customer Reviews (3)Write a review
Good at western-blot experiments. -
In experiments, the biocompatibility performed well. -
The experimental conditions are broad, and the experimental results are accurate and repeatable. -
Ask a Question for All CTSD Products
Required fields are marked with *
My Review for All CTSD Products
Required fields are marked with *